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Abstract (249 words) 1 
Objective: This multicenter, cross-sectional, non-interventional trial aimed to 2 
investigate adherence barriers to inhaled medicines when compared with oral 3 
medicines in Japanese patients with chronic obstructive pulmonary disease (COPD) 4 
and asthma. 5 
Methods: The self-reporting “Adherence Starts with Knowledge 20” (ASK-20) 6 
questionnaire was administered for adherence barriers of inhaled and oral medicines 7 
to outpatients with regular clinic attendance. 8 
Results: Patients with COPD and asthma reported different adherence barriers to 9 
inhaled medicines. Independent adherence barriers (odds ratio [95% confidence 10 
interval]) to inhaled medicines relative to those for oral medicines among patients with 11 
COPD and asthma were those related to item Q8 (“I know if I am reaching my health 12 
goals”; 2.49 [1.39–4.47]; p = 0.0022) and item Q2 (“I run out of my medicine because 13 
I do not get refills on time”; 2.69 [1.26–5.75]; p = 0.0127), respectively. Among 14 
patients with poor adherence to only inhaled medicines, those with COPD and 15 
asthma recognized item Q3 (“consuming alcohol and taking medicines”; 6.63 16 
[1.27–34.7]; p <0.05) and item Q1 (“forget to take medicines only sometimes”; 4.29 17 
[1.83–10.0]; p <0.05), respectively, were recognized as independent adherence 18 
barriers to inhaled medicines. The total ASK-20 scores and total barrier counts in 19 
4 
 
patients with poor adherence to inhaled medicines were significantly higher than in 1 
those without poor adherence among patients with asthma (p = 0.0057) but not those 2 
with COPD (p >0.05). 3 
Conclusion: These results will aid in personalizing education on adherence to 4 
inhaled medicines among patients with COPD and asthma. 5 
 6 
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Introduction 1 
Inhaled medicines play a central role in the long-term treatment of chronic respiratory 2 
diseases, such as chronic obstructive pulmonary disease (COPD) and asthma.1,2 The 3 
improvement of pharmacological adherence (adherence) to inhaled medicines might 4 
contribute to a better prognosis, as poor adherence often causes disease 5 
exacerbation and affects mortality in patients with COPD and asthma.3–8 Previous 6 
reports have demonstrated that adherence to inhaled medicines is worse than that to 7 
oral, injected, and transdermal medicines.9–12 In Japan, adherence to inhaled 8 
medicines has been reported to be significantly poorer than that to oral medicines in 9 
patients with COPD and asthma.13 10 
The Adherence Starts with Knowledge 20 (ASK-20) questionnaire was 11 
developed by Hahn et al. (2008) to identify adherence barriers. 14,15 The Japanese 12 
version of the ASK-20 questionnaire has already been validated in Japanese patients 13 
with asthma.16 Previous studies have demonstrated a good correlation between 14 
adherence and adherence barriers in patients with asthma using the ASK-20 15 
questionnaire.14–16 However, adherence barriers to inhaled medicines compared with 16 
oral medicines are still unclear in Japanese patients with COPD. 17 
In this regard, we have formulated three hypotheses. First, patients who require 18 
regular use of inhaled medicines, such as those with COPD and asthma, have 19 
6 
 
different barriers to inhaled medicines than they do to oral medicines. Second, there 1 
are differences in barriers to inhaled medicines between patients with COPD and 2 
asthma. Third, there are also differences in barriers to inhaled medicines between 3 
patients with COPD and asthma among patients with poor adherence to only inhaled 4 
medicines.  5 
The Kyushu Asthma Seminar Investigator Group conducted this multicenter, 6 
cross-sectional, non-interventional trial to investigate the adherence barriers to 7 
inhaled medicines among Japanese patients with COPD and asthma using the 8 
ASK-20 questionnaire. Understanding adherence barriers to inhaled medicines will 9 
help personalize education about adherence to medicines in Japanese with COPD 10 
and asthma.  11 
12 
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Methods 1 
Ethical approval 2 
The study was conducted in accordance with the Good Clinical Practice guidelines 3 
and was approved by the ethics board of each institute. The trial was registered in the 4 
University Hospital Medical Information Network (UMIN) Center (UMIN No. 5 
R000015329) on February 13, 2014. Physicians obtained written informed consent 6 
from every patient who met the inclusion criteria. 7 
 8 
Patients 9 
Outpatients with COPD (>40 years of age) and asthma (>20 years of age) who met 10 
the inclusion criteria—regular medication with prescriptions of at least one inhaled 11 
and one oral medicine each and regular clinic attendance with medical records since 12 
giving their consent to participate within at least six months before the start of the 13 
study—were enrolled at each institute. To investigate adherence in each patient, one 14 
inhaled and one oral medicine each was selected as the most important medicine 15 
among all regularly prescribed agents by each physician, without consulting with the 16 
patient (Supplementary Table 1). Patients with higher brain disorders, such as 17 
dementia, were excluded. Elderly patients (≥80 years of age) and those <20 years old 18 
were also excluded. Patients with other chronic pulmonary diseases, such as 19 
8 
 
bronchiectasis, interstitial pneumonitis, and pneumoconiosis, and other active 1 
pulmonary infectious diseases, such as mycobacterium and fungal infections, were 2 
also excluded. 3 
 4 
Study design 5 
After providing their written consent, patients were required to complete the Japanese 6 
version of the self-reported ASK-20 questionnaire for adherence to the selected 7 
inhaled and oral medicines.16 Two types of modified ASK-20 questionnaires (one for 8 
the inhaled medicines and one for the oral medicines) (Supplementary Table 1) were 9 
completed by each patient. To ensure the accurate completion of the ASK-20 10 
questionnaire, technical nurses or pharmacists at each institute provided support for 11 
the patients’ responses regarding inhaled and oral medicines. The nurses and 12 
pharmacists worked independently from the physicians and investigators.  13 
Patient characteristics—including the age, sex, body mass index (BMI), 14 
smoking habits, presence of comorbid diseases, disease control levels, adherence 15 
levels to the selected inhaled and oral medicines, and information on all regular 16 
inhaled and oral medications—were recorded.13,17 The presence of COPD was 17 
defined based on the following criteria: 1) age >40 years; 2) smoking history >0 18 
pack-years; 3) fixed airflow obstruction with a forced expiratory volume in 1 s 19 
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(FEV1)/forced vital capacity (FVC) ratio <70%; and 4) reversibility of FEV1 <12% and 1 
<200 mL after administration of bronchodilators in accordance with the Global 2 
Initiative for Chronic Obstructive Lung Disease (GOLD) guideline.1 The presence of 3 
asthma was defined based on a diagnosis by the physician in accordance with the 4 
Global Initiative for Asthma (GINA) guidelines.2 Poor disease control was recognized 5 
by a total COPD assessment test (CAT) score >10 points among patients with 6 
COPD18-20 and by well, partially, or uncontrolled asthma in accordance with the GINA 7 
guidelines among patients with asthma.2 Comorbid diseases were defined based on 8 
interview findings and information regarding all regular medicines prescribed to the 9 
total population (Supplementary Table 3). From medical records, physicians selected 10 
the best pre-bronchodilation values of FVC and FEV1 during stable disease status. 11 
Adherence to the selected inhaled and oral medicines within 6 months before 12 
enrolment was assessed based on the questionnaire findings and prescription refill 13 
methods, and poor adherence to medicines was defined as <80% of adherence to 14 
inhaled or oral medicine, as determined by either method.13, 21-24 All data were those 15 
values from within six months before enrolment.  16 
However, patients with asthma-COPD overlap (ACO) were excluded from the 17 
study. Physicians excluded patients with suspected ACO based on the presence of 18 
asthmatic factors, such as variable changes in the respiratory symptoms and the lung 19 
10 
 
function, among the patients with COPD at enrollment. However, 26 patients (12.3%) 1 
who had COPD-like features (suspected ACO) based on the criteria according to the 2 
GOLD guidelines1 after subsequent analyses among patients with asthma were 3 
accepted as having asthma in accordance with the physician’s diagnosis. Patients 4 
who required long-term home oxygen therapy and non-invasive positive pressure 5 
support ventilation were also excluded from the subsequent analyses. 6 
 7 
Statistical analyses 8 
Patient characteristics were expressed as the number (percentage) of patients or 9 
mean ± standard deviation (SD). The total ASK-20 scores and total barrier counts 10 
(TBCs) were calculated in accordance with the methods described in previous studies 11 
(Supplementary Table 2).14–16 To identify the independencies of adherence barriers to 12 
inhaled medicines, the proportions of patients who reported TBCs for each item were 13 
compared between inhaled and oral medicines by univariate and multivariate 14 
analyses. Patients were divided into two groups: those with and without poor 15 
adherence only to selected inhaled medicines, with the latter group including patients 16 
with good or poor adherence to the selected inhaled and oral medicines and poor 17 
adherence to only selected oral medicines. Adherence barriers for poor adherence to 18 
only inhaled medicines in each questionnaire item were identified by univariate and 19 
11 
 
multivariate analyses as follows: Dummy scores for the presence and absence of 1 
TBCs for inhaled or oral medicines were set as 1 and 0, respectively. When the 2 
dummy scores for inhaled medicines were higher than those for oral medicines, they 3 
were recognized as indicating the presence of barriers only to inhaled medicines. 4 
Data were compared between the groups using the unpaired t-test and chi-square 5 
test or the Fisher exact test with an expected frequency of <5.0 in cells >20%. To 6 
identify barriers for adherence to inhaled medicines, the odds ratio (OR) (95% 7 
confidence interval [CI] and p value) of each questionnaire item for inhaled medicines 8 
was analyzed by the chi-square or Fisher’s exact test in univariate and multivariate 9 
analyses. The nonparametric Spearman rank test was used for the correlation (r) 10 
analysis. Differences of p <0.05 were considered statistically significant. Statistical 11 
analyses were performed using the software package JMP version 9.0® (SAS 12 
Institute Japan Inc., Tokyo, Japan). 13 
14 
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Results 1 
Of the 381 patients (COPD, n = 140; asthma, n = 241) who gave their written consent, 2 
335 (COPD, n = 114; asthma, n = 221) were ultimately analyzed in this study (Fig. 1). 3 
The numbers (OR [95% CI]; p value) of patients with poor adherence to inhaled 4 
medicines (n = 25) (poor adherence to only inhaled medicines [n = 19] and poor 5 
adherence to both inhaled and oral medicines [n = 6]) among patients with COPD 6 
(5.31 [1.46–19.2]; p = 0.0135) and asthma (n = 57) (poor adherence to only inhaled 7 
medicines [n = 17] and poor adherence to both inhaled and oral medicines [n = 40]; 8 
9.53 [3.70–24.6]; p <0.0001) were significantly greater than those with poor 9 
adherence to oral medicines (11 patients with COPD: poor adherence to only oral 10 
medicines [n = 5] and poor adherence to both inhaled and oral medicines [n = 6]; and 11 
24 patients with asthma: poor adherence to only oral medicines [n = 17] and poor 12 
adherence to both inhaled and oral medicines [n = 7]) (Fig. 1). 13 
Table 1 presents a comparison of characteristics between patients with COPD 14 
and asthma. Patients with COPD were significantly older and had higher proportions 15 
of men (91.2%), smokers, and incidences of poor disease control than patients with 16 
asthma, whereas patients with asthma had significantly higher proportions of patients 17 
with chronic and seasonal rhinosinusitis and exhibited significantly better lung 18 
functions than patients with COPD. In regular treatment, the number of inhaled but 19 
13 
 
not oral medicines in the COPD group was significantly higher than that in the asthma 1 
group. In the comparison of diseases, the TBCs, but not the total ASK-20 scores, for 2 
oral medicines in patients with asthma were significantly higher than those in patients 3 
with COPD, whereas the total ASK-20 scores and TBCs showed no significant 4 
differences among the disease groups. However, regarding the correlation (r) 5 
between the ASK-20 questionnaire scores and adherence levels (%) via refill 6 
methods, the total ASK-20 scores and TBCs showed significantly negative 7 
associations with adherence with respect to inhaled (r = - 0.29, p <0.0001 and r = - 8 
0.29, p <0.0001, respectively) but not oral medicines (r = 0.07, p = 0.4800 and r = 9 
0.10, p = 0.3784, respectively) among patients with asthma. There was no correlation 10 
between inhaled (r = - 0.05, p = 0.6333 and r = - 0.08, p = 0.4317, respectively) and 11 
oral (r = - 0.02, p = 0.8112 and r = 0.10, p = 0.4982, respectively) medicines in 12 
patients with COPD. 13 
Fig. 2 presents the results of a comparison of the proportion of patients with 14 
adherence barriers identified for each ASK-20 item between inhaled and oral 15 
medicines. There were no significant differences in the total ASK-20 scores or TBCs 16 
between inhaled and oral medicines among the disease groups (Supplementary Fig. 17 
1). In the total study population, markedly high proportions of patients with adherence 18 
barriers to inhaled medicines reported adherence barriers because of items Q3 (“My 19 
14 
 
use of alcohol gets in the way of taking my medicine”) and Q8 (“I know if I am 1 
reaching my health goals”), whereas a relatively high proportion of patients with 2 
adherence barriers to oral medicines reported barriers because of item Q20 (“Have 3 
you not had your medicine with you when it was time to take it?”). In the COPD group, 4 
items Q7 (“I feel confident that each of my medicines will help me”) and Q8 were 5 
found to be related to higher proportions of patients with adherence barriers to 6 
inhaled medicines than oral medicines, whereas items Q1 (“I forget to take my 7 
medicines only sometimes”), Q6 (“I have felt sad, down, or blue during the past 8 
month”), and Q20 were related to higher proportions of patients with adherence 9 
barriers to oral medicines than inhaled medicines. In the asthma group, item Q2 (“I 10 
run out of my medicine because I do not get refills on time”) was related to higher 11 
proportions of patients with barriers to inhaled medicines than oral medicines, 12 
whereas item Q20 was related to higher proportions of patients with adherence 13 
barriers to oral medicines than inhaled medicines. 14 
The results of multivariate analyses (Table 2) revealed that, among the total 15 
study population and among patients with COPD, items Q3 (OR, 3.81 [95% CI, 16 
1.40–10.4]; p = 0.0087) and Q8 (2.49 [1.39–4.47]; p = 0.0022), respectively, were 17 
more frequently independent adherence barriers to inhaled medicines than to oral 18 
medicines. However, among patients with asthma, only item Q2 (2.69 [1.26–5.75]; p = 19 
15 
 
0.0127) was found to be an adherence barrier to inhaled medicines in a univariate 1 
analysis.  2 
Fig. 3 presents the results of a comparison of the total ASK-20 scores and TBCs 3 
for inhaled medicines between patients with (n = 59 [COPD, 19; asthma, 40]) and 4 
without (n = 276 [COPD, 95; asthma, 181]) poor adherence to only selected inhaled 5 
medicines. As shown in Fig. 3A, the total ASK-20 scores among patients with poor 6 
adherence to inhaled medicines were significantly higher than those among patients 7 
without poor adherence in the total study population (p = 0.0077) and in the asthma 8 
group (p = 0.0057) but not in the COPD group (p = 0.2881). As shown in Fig. 3B, the 9 
TBCs among patients with poor adherence to inhaled medicines were significantly 10 
higher than those among patients without poor adherence in the total study 11 
population (p = 0.0005) and in the asthma group (p = 0.0004) but not in the COPD 12 
group (p = 0.2452). 13 
Table 3 presents the ORs (95% CIs) for each item among adherence barriers to 14 
inhaled medicines in patients with poor adherence to only inhaled medicines relative 15 
to that in patients without poor adherence. The results of multivariate analyses 16 
revealed that, among patients with COPD, item Q3 (6.63 [1.27–34.7]; p = 0.0250) was 17 
an independent adherence barrier to inhaled medicines. In contrast, among the total 18 
study population and patients with asthma with poor adherence to inhaled medicines, 19 
16 
 
item Q1 was an independent adherence barrier to inhaled medicines (3.07 1 
[1.60–5.88] and 4.29 [1.83–10.0]; p = 0.0007 and 0.0008, respectively). 2 
3 
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Discussion 1 
To our knowledge, this is the first report to compare adherence barriers between 2 
inhaled and oral medicines among Japanese patients with COPD and asthma using 3 
the ASK-20 questionnaire. The ASK-20 questionnaire is useful for identifying the 4 
patient-specific adherence barriers using the total ASK-20 scores and TBCs.14-16 We 5 
demonstrated that the adherence to inhaled medicines was poorer than to oral 6 
medicines in patients with COPD and asthma.13 However, we were unable to identify 7 
the differences in the barriers between the different drug formulations based on the 8 
total ASK-20 scores and TBCs in patients with COPD and asthma.  9 
In the comparison of diseases, only the TBCs for oral medicines among patients 10 
with asthma were significantly higher than among those with COPD. The risk factors 11 
for higher TBCs in patients with asthma were not determined, although the 12 
correlations between high TBCs for oral medicines and the patient characteristics, 13 
including the age, gender, smoking status, disease control, lung function, and number 14 
of medicines, were analyzed (unpublished observation). The ASK-20 questionnaire 15 
includes the domains of lifestyles (item Q1 to Q6), attitude and behavior (Q7 and Q8), 16 
support from others or communication with the healthcare team (Q9 to Q12), barriers 17 
for medicines (Q13 to Q 15), and adherence to medicines (Q16 to Q20).14, 15 18 
Evaluating the score for each individual item in these domains may facilitate the 19 
18 
 
identification of patient-specific adherence barriers more efficiently than the total 1 
ASK-20 scores and TBCs. 2 
Personalized interventions to adherence barriers may help improve adherence 3 
to medicines, although adherence barriers may vary among patients.3, 25 Our study 4 
showed that the total ASK-20 scores and TBCs were negatively associated with 5 
adherence levels with respect to only inhaled medicines, as per the refill method in 6 
patients with asthma. The weak correlation between adherence barriers and 7 
adherence levels may be due to our assessment of the last six months of adherence, 8 
as previous studies demonstrated a good correlation between the daily or 9 
most-recent-two-week barriers and adherence.3, 14-16 In addition, our finding of no 10 
correlation between adherence barriers and adherence levels in patients with COPD 11 
may have been due to the sample size. 12 
A previous study reported embarrassment or annoyance regarding using or 13 
carrying medicines to be a barrier to inhaled medicines;26 however, that study did not 14 
investigate adherence barriers among patients with COPD. Identifying patient-specific 15 
adherence barriers is important for managing patients with chronic diseases.14, 15 In 16 
our study, the results indicated differences in independent adherence barriers to 17 
inhaled medicines compared with those to oral medicines among the total population, 18 
patients with COPD, and those with asthma. The total population is recognized as a 19 
19 
 
cohort of patients who require the regular use of inhaled medicines. These patients 1 
considered alcohol consumption to be an independent barrier to inhaled medicines to 2 
a greater extent than to oral medicines; however, why alcohol consumption was 3 
considered a barrier to adherence to inhaled medicines is unclear. Patients may 4 
simply forget to take their inhaled medicines or may be concerned with the interactive 5 
effects between alcohol and inhaled medicines during or after alcohol consumption. 6 
In comparing COPD and asthma patients, patients with COPD reported that reaching 7 
their health-related goals was an independent adherence barrier to inhaled medicines. 8 
Our study showed that the patients with COPD included a significantly larger 9 
population with poorly controlled diseases that used a larger variety of regular inhaled 10 
medicines than the patients with asthma. Furthermore, the patients with COPD 11 
seemed more likely to recognize their own respiratory disease as incurable and their 12 
own inhaled medicines as insufficient treatments than those with asthma. Recognition 13 
of diseases and medication beliefs may affect adherence barriers for inhaled 14 
medicines in patients with COPD, because patients with COPD may recognize their 15 
own disease as an incurable disease.27-29  16 
In addition, most patients with COPD enrolled in this study were older than those 17 
with asthma. Aging is a predictor of poor adherence to medicines in patients with 18 
COPD.30, 31 Albrecht et al. reported that depression reduced adherence in older 19 
20 
 
patients with COPD.32 Aging and mood disorders may affect the recognition of 1 
personal health goals;30, 32 however, the interaction between aging and the 2 
recognition of heath goals is still unclear. In contrast, patients with asthma reported 3 
that they refilled inhaled medicines in a timely manner after depleting their stocks less 4 
frequently than for oral medicines. The characteristics of asthma, not but COPD, 5 
seem to explain why patients do not take inhaled medicines when they are depleted. 6 
Asthmatic symptoms vary despite regular treatments. Indeed, a better controlled 7 
disease and less-frequent treatment due to a lack of perceived symptoms are known 8 
to be the main reasons for poor adherence in asthma.33, 34 As such, less-intense 9 
symptoms may lead to a patient forgetting to take inhaled medicines.  10 
Poor adherence to inhaled medicines is affected by barriers to inhaled 11 
medicines.16, 27 In our study, patients with poor adherence to only inhaled medicines 12 
had significantly higher total ASK-20 scores and TBCs to inhaled medicines than 13 
those without poor adherence in the total population and the asthma group but not in 14 
the COPD group. Poor adherence to medicines may be linked to adherence barriers. 15 
Among patients with COPD, those with poor adherence to inhaled medicines 16 
recognized alcohol consumption as a greater independent barrier to inhaled 17 
medicines than to oral medicines. However, the proportion of patients with TBCs for 18 
item Q3 was small (<10%) among patients with COPD. An individual’s alcohol 19 
21 
 
consumption may contribute to the development of a personalized education 1 
approach for inhaled medicines in patients with poor adherence to inhaled medicines 2 
among those with COPD. Among patients with asthma, those with poor adherence to 3 
inhaled medicines recognized forgetfulness about taking their medicines sometimes 4 
as a greater independent barrier to inhaled medicines than to oral medicines. As 5 
previously mentioned, forgetting to take inhaled medicines may be associated with 6 
asthmatic symptoms and the degree of control among patients with poor adherence, 7 
similar to our findings in the cohort of patients with asthma.31, 34 Reminders or 8 
electronic trackers as interventions may help improve adherence to inhaled 9 
medicines, if patients with poor adherence simply forget to take their medicine.35 10 
This study has some limitations. First, a selection bias might have influenced the 11 
results, as we selected patients with good pharmacological persistence. The absence 12 
of differences in the total ASK-20 scores or TBCs was possible, as over 70% of the 13 
enrolled patients had good adherence to inhaled and oral medicines. Previous 14 
studies have reported persistence rates of 10%–15% for inhaled medicines after a 15 
year among patients with asthma.36, 37 Second, since there are no specific tools 16 
available for the measurement of adherence barriers to inhaled medicines, we used 17 
the ASK-20 questionnaire with some modifications. Third, pharmacological 18 
adherence was evaluated not by direct methods but rather by indirect methods (i.e. 19 
22 
 
questionnaire and prescription refill surveys). Fourth, the characteristics of patients 1 
with suspected ACO were not assessed in this study. Fifth, among all inhaled and oral 2 
medicines, we only selected one medicine each for the comparison of adherence 3 
between the two medication types. This selection bias might have affected our results. 4 
Sixth, the sample size of the COPD group might be considered inadequate for the 5 
statistical analyses (Supplementary Appendix). Further studies are necessary to 6 
address these limitations. 7 
In conclusion, we comparatively analyzed adherence barriers to inhaled and 8 
oral medicines among patients with COPD and asthma using the ASK-20 9 
questionnaire. We observed differences in the underlying factors for adherence 10 
barriers between patients with COPD and asthma. In addition, among patients with 11 
COPD and asthma, those with and without poor adherence to inhaled medicines 12 
differed in terms of some barriers to inhaled medicines. We believe that our results 13 
will aid in the personalization of education for adherence to inhaled medicines among 14 
Japanese patients with COPD and asthma who require inhaled medications. 15 
16 
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 1 
Table 1 Characteristics of the total study population and patients with COPD or asthma  2 
 3 
Characteristics 
Total 
n = 335 
COPD 
n = 114 
Asthma 
n = 221 
COPD vs asthma 
p value  
Age, years 64.5 ± 12.3 71.1 ± 6.2  61.1 ± 13.3 < 0.0001 
Male, n (%) 186 (55.5) 104 (91.2) 82 (37.1) < 0.0001 
Body mass index, kg/m2 23.3 ± 4.7 21.6 ± 4.2 24.2 ± 4.7 < 0.0001 
Smoking habit, Cu/ex/non, n (%) 42/147 /146 
(12.5/43.9/43.6) 
15/99/0 
(13.2/86.8/0) 
27/48/146 
(12.2/21.7/66.1) < 0.0001 
Smoke index, pack-year 25.6 ± 32.9 57.9 ± 29.3 8.9 ± 19.6 < 0.0001 
No. of comorbid diseases per patient 2.6 ± 2.0 2.6 ± 1.9 2.6 ± 2.0 1.0 
No. of patients with chronic and seasonal 
rhinosinusitis, n (%) 
55 (16.4) 8 (7.0) 47 (21.2) 0.0006 
Poor controlled diseases, n (%) 129 (38.5) 74 (64.9) 55 (24.9) < 0.0001 
Lung function tests     
FVC, L 2.8 ± 0.8 2.8 ± 0.7 2.8 ± 0.8 0.5 
% predicted FVC, % 92.2 ± 19.3 87.0 ± 21.9 94.9 ± 17.2 0.0003 
FEV1, L 1.7 ± 0.7 1.3 ± 0.6 1.9 ± 0.7 < 0.0001 
%FEV1 predicted, % 70.5 ± 25.4 50.2 ± 22.0 80.9 ± 20.2 < 0.0001 
FEV1/FVC ratio 61.3 ± 17.4 45.5 ± 14.3 69.5 ± 12.6 < 0.0001 
Treatment for COPD or asthma 335 (100) 114 (100) 221 (100)  
ICS alone 38 (11.3) 0 (0) 38 (17.2) < 0.0001 
LABA alone 14 (4.2) 14 (12.3) 0 (0) < 0.0001 
LAMA alone 26 (7.8) 26 (22.8) 0 (0) < 0.0001 
ICS–LABA combinations 186 (55.5) 16 (14.0) 170 (76.9) < 0.0001 
ICS–LAMA combinations 5 (1.5) 5 (4.4) 0 (0) 0.0043 
LAMA–LABA combinations 21 (6.3) 21 (18.4) 0 (0) < 0.0001 
ICS–LABA–LAMA triplets 45 (13.4) 32 (28.1) 13 (5.9) < 0.0001 
No. of regular inhaled medicines 
(devices), n (range) 
1.3 ± 0.5 
(1 to 3) 
1.5 ± 0.5 
(1 to 3) 
1.1 ± 0.4 
(1 to 3) < 0.0001 
No. of regular oral medicines,  
n (range) 
4.5 ± 3.4 
(1 to 19) 
4.9 ± 4.0 
(1 to 19) 
4.3 ± 3.0 
(1 to 18) 0.1 
ASK-20 questionnaire     
For inhaled medicines     
Total ASK-20 scores 35.1 ± 9.1 34.1 ± 9.2 35.4 ± 9.0 0.5 
TBCs 3.1 ± 2.6 2.9 ± 2.5 3.4 ± 2.6 0.1 
For oral medicines     
Total ASK-20 scores 34.0 ± 9.0 33.5 ± 9.0 34.9 ± 8.7 0.1 
TBCs 2.9 ± 2.5 2.6 ± 2.5 3.5 ± 2.6 0.0008 
 4 
Notes: Data are presented as numbers (percentages) of patients and mean ± standard deviation. For 5 
asthma, the number (%) of patients with steps I, II, III, IV, and V, based on GINA treatment steps, were 6 
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0 (0), 40 (11.9), 113 (33.7), 48 (14.3), and 20 (6.0), respectively. For COPD, the number (%) of patients 1 
with mild (%FEV1 predicted >80%), moderate (50% < %FEV1 predicted <80%), severe (30% < %FEV1 2 
predicted <50%), and very severe (%FEV1 predicted <30%) airflow obstruction levels based on the 3 
GOLD guideline were 11 (9.6), 44 (35.6), 33 (28.9), and 26 (22.8), respectively. The mean (SD) total 4 
CAT score was 14.1 (8.1) in patients with COPD. 5 
 6 
Abbreviations: COPD, chronic obstructive pulmonary disease; Cu/Ex/Non, current/ex/non-smoker; 7 
FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroid; LABA, 8 
long-acting β2 agonist; LAMA, long-acting muscarinic antagonist; TBCs, total barrier counts 9 
 10 
11 
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 1 
Table 2 Odds ratio (95% CI) of each ASK-20 item between patients with adherence barriers to inhaled 2 
when compared with oral medicines by univariate and multivariate analyses 3 
 4 
Item 
Univariate analyses  Multivariate analyses 
Odds ratio (95% CI) p value  Odds ratio (95% CI) p value 
Total study population 
Q3. 
My use of alcohol gets in the way 
of taking my inhaled or oral 
medicines. 
3.97 (1.46, 10.8) 0.0057a  3.81 (1.40, 10.4) 0.0087a 
Q8. 
I know if I am reaching my health 
goals. 
1.39 (1.01, 1.89) 0.0480a  1.35 (0.99, 1.85) 0.1 
COPD       
Q7. 
I feel confident that each one of my 
inhaled or oral medicines will help 
me. 
2.63 (1.23, 5.65) 0.0173a  1.59 (0.69, 3.66) 0.3 
Q8. 
I know if I am reaching my health 
goals. 
2.84 (1.66, 4.87) 0.0002a  2.49 (1.39, 4.47) 0.0022a 
Asthma 
Q2. 
I run out of inhaled or oral 
medicine because I do not get 
refills on time. 
2.69 (1.26, 5.75) 0.0127a    
Notes: In univariate analyses, odds ratio (95% CI; p value) for each item was calculated on the basis 5 
of comparison between patients with barriers to inhaled and oral medicines by the Fisher exact test 6 
(Full data in Supplementary Table 4). The bolded words were arranged in each ASK-20 item by 7 
investigators. 8 
a p <0.05 when compared with oral medicines, b p < 0.05 when compared with inhaled medicines 9 
 10 
Abbreviations: ASK-20, Adherence Starts with Knowledge 20; CI, confidence interval; COPD, chronic 11 
obstructive pulmonary disease 12 
13 
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 1 
Table 3 Odds ratio (95% CI) of each ASK-20 item on barriers to inhaled medicines in patients with poor 2 
adherence to only inhaled medicines relative to patients without poor adherence 3 
 4 
Items 
Univariate analyses  Multivariate analyses 
Odds ratio (95% CI) p value  Odds ratio (95% CI) p value 
Total study population 
Q1. 
I forget to take my inhaled or oral 
medicines only some times. 
4.21 (2.33, 7.60) < 0.0001a  3.07 (1.60, 5.88) 0.0007a 
Q4. 
I worry about how the inhaled or 
oral medicines will affect my sexual 
health. 
3.36 (1.15, 9.83) 0.0317a  2.05 (0.58, 7.26) 0.3 
Q5. 
I sometimes forget things that are 
important to me. 
2.57 (1.36, 4.86) 0.0051a  1.39 (0.68, 2.85) 0.4 
Q16. 
Have you taken an inhaled or oral 
medicine more or less often than 
prescribed? 
2.91 (1.64, 5.18) 0.0003a  1.71 (0.90, 3.26) 0.1 
Q17. 
Have you skipped or stopped taking 
an inhaled or oral medicine 
because you did not think it was 
working? 
4.13 (1.71, 9.94) 0.0024a  2.10 (0.69, 6.40) 0.2 
Q18. 
Have you skipped or stopped taking 
an inhaled or oral medicine 
because it made you feel bad? 
3.78 (1.45, 9.86) 0.0089a  1.32 (0.39, 4.52) 0.7 
COPD 
Q3. 
My use of alcohol gets in the way of 
taking my inhaled or oral medicines. 
8.18 (1.66, 40.2) 0.0144a  6.63 (1.27, 34.7) 0.0250a 
Q17. 
Have you skipped or stopped taking 
an inhaled or oral medicine 
because you did not think it was 
working? 
4.80 (1.16, 19.9) 0.0410a  3.72 (0.81, 17.1) 0.1 
Asthma 
Q1. 
I forget to take my inhaled or oral 
medicines only sometimes. 
5.76 (2.64, 12.5) < 0.0001a  4.29 (1.83, 10.0) 0.0008a 
Q4. 
I worry about how the inhaled or 
oral medicine will affect my sexual 
health. 
3.55 (1.07, 11.8) 0.0451a  2.18 (0.52, 9.14) 0.3 
Q5. 
I sometimes forget things that are 
important to me. 
2.34 (1.07, 5.15) 0.0407a  1.10 (0.45, 2.70) 0.8 
Q16. 
Have you taken an inhaled or oral 
medicine more or less often than 
prescribed? 
3.06 (1.52, 6.18) 0.0023a  1.79 (0.82, 3.91) 0.1 
Q17. 
Have you skipped or stopped taking 
an inhaled or oral medicine 
because you did not think it was 
working? 
3.82 (1.24, 11.7) 0.0237a  1.64 (0.38, 6.99) 0.5 
Q18. 
Have you skipped or stopped taking 
an inhaled or oral medicine 
because it made you feel bad? 
3.55 (1.07, 11.8) 0.0451a  1.00 (0.20, 4.95) 1.0 
 5 
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Notes: In univariate analyses, odds ratio (95% CI; p value) for each item was calculated on the basis 1 
of comparison between patients with barriers to inhaled medicines and oral medicines by the Fisher 2 
exact test (Full data in Supplementary Table 5).  3 
a p < 0.05 when compared with patients without poor adherence to only inhaled medicines. 4 
 5 
Abbreviations: ASK-20, Adherence Starts with Knowledge 20; CI, confidence interval; COPD, chronic 6 
obstructive pulmonary disease 7 
 8 
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Figure Legends 1 
Fig. 1. Study design.  2 
 3 
 4 
 5 
 6 
ASK-20, Adherence Starts with Knowledge 20; COPD, chronic obstructive pulmonary 7 
disease. 8 
 9 
10 
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 1 
Fig. 2. A comparison of the proportion of patients with an adherence barrier 2 
indicated for each ASK-20 item between inhaled and oral medicines. 3 
 4 
 5 
The proportions of patients (%) are presented as bars with values. Patients with 6 
adherence barriers to inhaled and oral medicines are represented by black and white 7 
bars, respectively. The bolded words were arranged in each AKS-20 item by 8 
investigators. ap <0.05 when compared with oral medicines, bp <0.05 when compared 9 
with inhaled medicines. ASK-20, Adherence Starts with Knowledge 20; COPD, 10 
chronic obstructive pulmonary disease. 11 
12 
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 1 
Fig. 3. A comparison of the total ASK-20 scores (A) and total barrier counts (B) 2 
to inhaled medicines between patients with and without poor adherence to only 3 
inhaled medicines. 4 
 5 
 6 
 7 
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The values are presented as the median and 95% confidence interval (CI). The 1 
median values (upper and lower quintiles) are presented as boxes, and the maximum 2 
and minimum values of the 95% CI are presented as the upper and lower whiskers, 3 
respectively. Box-and-whisker plots with solid and dotted lines present the values for 4 
patients with and without poor adherence to only inhaled medicines, respectively. 5 
Outlier values are presented as open dots. ASK-20, Adherence Starts with 6 
Knowledge 20; CI, confidence interval; COPD, chronic obstructive pulmonary 7 
disease; NS, not significant.  8 
